Академический Документы
Профессиональный Документы
Культура Документы
6137
Serum Adiponectin at Diagnosis as a Predictor of Breast Cancer Survival
RESEARCH ARTICLE
Department of Preventive Medicine, Kangwon National University School of Medicine, 2Department of Biomedical Sciences, Seoul
1
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea, 4Department of Surgery, University of Ulsan
3
Results
Figure 1. Flow Diagram of the Study Population After a median follow-up of 4.2 years, there were 109
Selection events including 19 deaths from any cause among all 370
6138 Asian Pacific Journal of Cancer Prevention, Vol 15, 2014
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.15.6137
Serum Adiponectin at Diagnosis as a Predictor of Breast Cancer Survival
patients. (Table 1) summarized the patients characteristics the association was disappeared the significance after
and univariate and multivariateadjusted HRs for DFS by adjustment for covariates.
patients characteristics. Participants of this study had an In all patients, the median (25 and 75 percentile) of
average age of 46.6 years and the subject of DFS event adiponectin and leptin were measured at 9.7ug/ml (6.9-
had an average age of 46.2 years. Most patients were 13.2ug/ml) and 8.0ng/ml (6.6-9.3ng/ml), respectively.
premenopausal (64.0%) and had a BMI less than 25 kg/ There was an inverse correlation between serum
m2 (77.8%). In the multivariate analysis, the TNM stage adiponectin and leptin level in the participants (r=-0.133;
remained as independent and significant prognostic factors p=0.01). (Table 2) shows the distributions of patients
for DFS (p<0.001), and ER status was shown in marginal characteristics according to the tertile (low, middle, and
association with DFS (HR=1.73, p=0.06). PR status, high) of adiponectin and leptin. Women with higher
histological and nuclear grade, adjuvant chemotherapy, adiponectin levels (Ptrend=0.02) or with lower leptin levels
and hormone therapy was associated with DFS, but (Ptrend<0.01) were more likely to be heavier than women
Table 1. Hazard Ratios for Disease-Free Survival of 370 Breast Cancer Cases
No. (%) Event HR HR adj1 HR adj2
Age(meanSD) 46.610.6 46.211.4
39 yr old 100 (27.0) 34 (31.2) Ref Ref Ref
40-49 yr old 135 (36.5) 32 (29.4) 0.67 (0.41-1.09) 0.89(0.52-1.50) 1.04(0.59-1.83)
50 yr old 135 (36.5) 43 (39.5) 0.86 (0.55-1.36) 1.01(0.61-1.69) 1.07(0.62-1.85)
Menopause status
pre 235 (64.0) 66 (60.6) Ref Ref Ref
post 132 (36.0) 43 (39.5) 1.19 (0.81-1.75) 1.08 (0.56-2.05) 1.22 (0.62-2.39
BMI(kg/m2)
< 25 288 (77.8) 80 (73.4) Ref Ref Ref
25 82 (22.2) 29 (26.6) 1.14 (0.75-1.75) 1.07 (0.67-1.71) 1.03 (0.63-1.70)
TNM
0 - I 160 (44.7) 28 (27.2) Ref Ref Ref
II 130 (36.3) 38 (36.9) 1.43 (0.89 - 2.28) 1.30 (0.79-2.15) 1.24 (0.69-2.22)
III-IV 68 (19.0) 37 (35.9) 3.35 (2.09 - 5.38) 3.12 (1.89-5.13) 2.96 (1.67-5.26)
P trend <0.0001 P trend <0.0001 P trend <0.0001
ER
Positive 221 (60.8) 47 (45.2) Ref Ref Ref
Negative 142 (39.1) 57 (54.8) 2.33 (1.58-3.44) 1.58 (0.93-2.68) 1.73 (0.98-3.07)
PR
Positive 205 (56.6) 44 (42.3) Ref Ref Ref
Negative 157 (43.4) 60 (57.7) 2.10 (1.42-3.11) 1.39 (0.82-2.35) 1.43 (0.79-2.58)
Histologic grade
I-II 178 (56.7) 37 (40.7) Ref Ref Ref
III 136 (43.3) 54 (59.3) 2.07 (1.35-3.15) 1.06 (0.64-1.76) 1.25 (0.55-2.80)
Nuclear grade
I-II 190 (57.1) 42 (43.3) Ref Ref Ref
III 143 (42.9) 55 (6.7) 1.89 (1.26-2.83) 0.95 (0.58-1.55) 0.82 (0.36-1.83)
Adjuvant chemotherapy
Yes 241 (67.9) 86 (83.5) Ref Ref Ref
No 114 (32.1) 17 (16.5) 2.62 (1.54-4.47) 2.27 (1.24-4.17) 1.84 (0.94-3.59)
Radiotherapy
Yes 215 (59.9) 57 (54.3) Ref Ref Ref
No 144 (40.1) 48 (45.7) 0.73 (0.50-0.50) 0.78 (0.52-1.16) 0.81 (0.53-1.24)
Hormone chemotherapy
Yes 236 (66.1) 49 (46.7) Ref Ref Ref
No 121 (33.9) 56 (53.3) 0.36 (0.25-0.53) 0.43 (0.20-0.94) 0.57 (0.22-1.47)
*Event means the number of recurrence and death; Adj: adjusted for age, bmi, TNM, ER and PR status; Adj: adjusted for Adj and histological and nuclear grade
Table 4. Multivariate HR (95%CIs) of Breast Cancer Survival by Plasma Adiponectin Level Among Women
with Time and Normal Weight (BMI<25m/kg)
Adiponectin Premenopusal women (n, %) Postmenopausal women
level All Event HR* (95%CI) All Event HR (95%CI)
Low 18 (25.7) 11 (31.4) 1.00 12 (33.3) 8 (42.1) 1.00
Middle 21 (30.0) 12 (34.3) 1.11 (0.41-3.03) 11 (30.6) 5 (26.3) 0.25 (0.06-1.06)
High 31 (44.3) 12 (34.3) 0.57 (0.21-1.55) 13 (36.0) 6 (31.6) 0.15 (0.03-0.71)
P trend 0.22 0.02
*Adjusted for age, BMI, ER & PR status, TNM, histological and nuclear grade; Event means the number of recurrence or death
None
Remission
Persistence or recurrence
Newly diagnosed without treatment